Home LiteratureArticle Details
PMID: 2559316 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

New Escherichia coli gyrA and gyrB mutations which have a graded effect on DNA supercoiling.

Molecular & general genetics : MGG ·Vol. 219 ·No. 1-2 ·1989-10-00 ·Pages 306-12

Aleixandre V, Urios A, Herrera G, Blanco M

Abstract

We isolated new gyrA and gyrB mutations in Escherichia coli which have a graded effect on DNA supercoiling. The mutants, selected respectively for resistance to nalidixic acid and coumermycin, were sorted by means of a rapid in vivo assay of DNA gyrase activity (Aleixandre and Blanco 1987). Cells carrying a gyrB (Cour) mutation usually showed a decrease in DNA supercoiling, which would indicate a reduction in gyrase activity. In contrast, most of the gyrA (Nalr) mutations had no significant effect on DNA supercoiling. Moreover, they conferred a high level of resistance to nalidixic acid and other quinolones, thus being similar to the gyrA (Nalr) mutants currently used. We also detected rare gyrA mutants showing a reduction in DNA gyrase activity. These mutants were, in addition, resistant to only low concentrations of quinolones, which allowed us to use the phenotype of partial quinolone resistance as an indicator to score gyrA mutations affecting DNA supercoiling. When gyrB mutations were introduced into the gyrA mutants, these became more sensitive to quinolones and a decrease in supercoiling was observed. Moreover, the topA10 mutation sensitized gyrA (Nalr) cells to quinolones. We conclude therefore that the GyrA-dependent quinolone resistance is diminished as a consequence of the reduction either in topoisomerase I or gyrase activities.

MeSH Terms
Aminocoumarins Ampicillin/pharmacology Anti-Infective Agents/pharmacology Coumarins/pharmacology DNA Topoisomerases, Type I/metabolism DNA Topoisomerases, Type II/genetics,metabolism DNA, Bacterial/metabolism DNA, Superhelical/metabolism Drug Resistance, Microbial/genetics Escherichia coli/genetics Mutation Nalidixic Acid/pharmacology Plasmids
Chemicals
Aminocoumarins Anti-Infective Agents Coumarins DNA, Bacterial DNA, Superhelical Nalidixic Acid Ampicillin DNA Topoisomerases, Type I DNA Topoisomerases, Type II coumermycin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Aleixandre V
Instituto de Investigaciones Citológicas, Centro asociado del CSIC, Valencia, Spain.
Urios A
Herrera G
Blanco M
References (22)
22 references, click to expand
  1. Effects of DNA gyrase inhibitors in Escherichia coli topoisomerase I mutants.
    J Bacteriol. 1986 Oct;168(1):276-82 PMID: 3019999
  2. Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition.
    Proc Natl Acad Sci U S A. 1981 May;78(5):2747-51 PMID: 6265907
  3. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.
    Proc Natl Acad Sci U S A. 1977 Nov;74(11):4772-6 PMID: 337300
  4. Biology of bacterial deoxyribonucleic acid topoisomerases.
    Microbiol Rev. 1984 Dec;48(4):273-89 PMID: 6097803
  5. Quinolone-resistant mutations of the gyrA gene of Escherichia coli.
    Mol Gen Genet. 1988 Jan;211(1):1-7 PMID: 2830458
  6. Lambda transducing phages for the nalA gene of Escherichia coli and conditional lethal nalA mutations.
    Mol Gen Genet. 1978 Nov 29;167(2):129-37 PMID: 366382
  7. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.
    Biochemistry. 1989 May 2;28(9):3886-94 PMID: 2546585
  8. DNA supercoiling in gyrase mutants.
    J Bacteriol. 1984 May;158(2):397-403 PMID: 6327603
  9. Inhibitors of DNA topoisomerases.
    Biochemistry. 1988 Apr 5;27(7):2253-9 PMID: 2838070
  10. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.
    Proc Natl Acad Sci U S A. 1985 Jan;82(2):307-11 PMID: 2982149
  11. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.
    Proc Natl Acad Sci U S A. 1977 Nov;74(11):4767-71 PMID: 200930
  12. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase.
    Proc Natl Acad Sci U S A. 1976 Dec;73(12):4474-8 PMID: 794878
  13. DNA topoisomerases.
    Annu Rev Biochem. 1985;54:665-97 PMID: 2992360
  14. Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes.
    Cell. 1982 Nov;31(1):35-42 PMID: 6297751
  15. Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes.
    Cell. 1982 Nov;31(1):43-51 PMID: 6297752
  16. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA.
    Biochemistry. 1989 May 2;28(9):3879-85 PMID: 2546584
  17. Pedigrees of some mutant strains of Escherichia coli K-12.
    Bacteriol Rev. 1972 Dec;36(4):525-57 PMID: 4568763
  18. Heterogeneity in the level of ampicillin resistance conferred by pBR322 derivatives with different DNA supercoiling.
    Mol Gen Genet. 1987 Aug;209(1):56-60 PMID: 3312957
  19. Genetic analysis of mutations that compensate for loss of Escherichia coli DNA topoisomerase I.
    J Bacteriol. 1985 Jun;162(3):1173-9 PMID: 2987184
  20. DNA topoisomerases.
    Annu Rev Biochem. 1981;50:879-910 PMID: 6267993
  21. Regulation of DNA supercoiling in Escherichia coli.
    Cold Spring Harb Symp Quant Biol. 1983;47 Pt 2:763-7 PMID: 6305584
  22. The genetic control of DNA supercoiling in Salmonella typhimurium.
    EMBO J. 1984 Aug;3(8):1745-52 PMID: 6090123
Article Info
Journal
Molecular & general genetics : MGG
Abbr.
Mol Gen Genet
ISSN
0026-8925
Published
1989-10-00
Pages
306-12
Language
English
Region
Germany
NLM ID
0125036
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]